Vaxxinity, Inc. is a biotech company based in Dallas, Texas, that focuses on developing product candidates for human use in the neuroscience and coronavirus fields. The company is working on developing several product candidates for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, as well as migraines and to combat SARS-CoV-2 through their UB-612 development in phase 3 of clinical trials. Vaxxinity was founded in 2014 and is working hard towards the improvement of human health.